Science & Research at a Glance

2026 RESEARCH HIGHLIGHTS

FOCUS AREA	INITIATIVE AND GOAL	DATE / STATUS
Personalized Medicine at FDA	Published “The Scope & Significance of Progress in 2025,” documenting advances in personalized medicine reflected in FDA approvals during 2025.	May 21, 2026
Clinical impact of biomarker testing gaps	Published research quantifying the clinical consequences of biomarker testing gaps in metastatic lung cancer, including approximately 20,900 life-years lost.	August 2026
MRD testing and guidelines	Developed NCCN recommendations for bladder and colorectal cancers. Published “The Molecular Watchman” in The ASCO Post on October 6, 2026, covering MRD testing for treatment and surveillance.	October 6, 2026
Payer evidence, coverage, and access	Advancing payer-focused research on evidence requirements, coverage, reimbursement, implementation, and patient access, including collaboration opportunities with UCSF/TRANSPERS.	Active:roundtables planned

Science & Research at a Glance

FOCUS AREA	INITIATIVE AND GOAL	STAGE
Precision oncology gaps	Conducting follow-on research to the 2022 study to identify where eligible patients are lost across the precision oncology pathway and where implementation interventions may improve access to personalized care.	Underway
Precision oncology roadmap	Advancing the Roadmap Brief from gap identification to implementation, beginning with biomarker test ordering and treatment decision-making, supported by baseline data, stakeholder action plans, and measurable outcomes.	Publication expected October 2026
Advanced genomic testing	Exploring work with payers, employers, and clinical trial networks to expand comprehensive genomic profiling and inform treatment decisions.	Exploratory
Infectious disease	Collaborating on an educational initiative using expert focus groups to develop clinical pathways for metagenomic sequencing.	Underway
Neurology and neurodegenerative disease	Developing evidence and implementation initiatives across Alzheimer's disease, multiple sclerosis, Parkinson's disease, and related areas, with emphasis on biomarkers, care pathways, reimbursement, and patient access.	Underway

FOCUS AREA	INITIATIVE AND GOAL	STAGE
Rare ~~disease~~ and genetic disease	Building an evidence-development portfolio focused on earlier diagnosis, genomic and biomarker testing, treatment pathways, reimbursement, patient access, and real-world implementation, aligned with FDA priorities to advance rare disease science and accelerate access to innovative therapies.	Underway
Women's health	Developing an evidence-development portfolio focused on earlier diagnosis, biomarker and multi-omic testing, individualized treatment, and implementation across endometriosis, maternal health, menopause, and other areas of women's health.	Underway
Patient-centered research agenda	Planning a follow-up assessment of progress against the 45 research priorities established in 2020 and identifying persistent and emerging patient-centered research gaps.	Underway
Evidence Development Advisory Committee	Establishing a cross-disciplinary SME advisory committee to identify shared implementation gaps across disease areas and guide scientific and strategic direction across PMC's research portfolio.	In development
sPMC academic research network	Building university-based research chapters to support PMC-directed evidence-development projects, generate research outputs, and develop a pipeline of future personalized medicine talent.	Underway